Vaccine Vision

Vaccines, with few exceptions, are known somewhat pejoratively as jabs (Fierce Vaccines Weekly Newsletter) and require refrigeration. Vaccines, in the main, are administered by intramuscular injection by trained health care professionals. The major cost of most vaccines is not the vaccine sales price from the Pharmaceutical Industry. Rather, the major cost is the distribution of the vaccines and their administration. Distribution requires a cold chain which means refrigeration which in turn means reliable electricity. Administration requires a health care professional who can maintain sterility of the vaccine from the vial, to a hypodermic syringe and needle, to intramuscular injection. For example, the breakdown of the reimbursements in October 2015 for a flu shot was $12 for the vaccine, and $33 for the administration of the vaccine.

Verndari intends to reduce the dependence on the cold chain and the health care professional. Verndari has developed and applied for patents for our MicroArray Patch (MAP) design and an automated MicroArray Manufacturing System (MAP MS).  Our vaccines will be stable at room temperature and are administered with a painless skin patch. The manufacturing process is robust, inexpensive and can be manufactured on a large scale.   Our MicroArray Patch is a platform for delivering existent and new vaccines.  This design will substantially lower the cost of vaccines by eliminating the need for a hypodermic needle, eliminating the need for highly paid medical professionals to administer a vaccine and by eliminating dependence on the cold chain.

Verndari is also developing a rapid response vaccine platform technology capable of responding to changes in influenza within weeks. This rapid response platform technology could also address other epidemic and biological threats.

The worldwide market for vaccines today is approximately $15 billion and growing at over 12% per year. In developed countries, vaccines have had a profound effect by preventing at least twelve infectious diseases in children. Much work remains to be done, especially globally.

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

Dr. Jan A. Van Prooyen
Non-Executive Chairman of the Board

Jan graduated from West Point in 1966, received a Ph.D. in nuclear engineering from the University of Virginia, and completed a one-year fellowship at the Kennedy School of Government, Harvard University. His expertise includes project management, chemical and biological defense technology, and nuclear and missile defense systems. Jan’s Army career included leadership assignments focused on the acquisition of major defense systems, chemical-biological defense technology, missile defense technology, nuclear weapons, and developmental testing. He led two major research, development, and engineering centers, two national test ranges, and a chemical munitions storage facility.

After thirty years with the United States Army, he retired in 1996 as a Major General, and subsequently became a senior vice president and partner at the Bechtel Corporation. Jan then spent 13 years with Bechtel where he was president of Bechtel’s 5,000-person Defense and Space business (2003-2006).  Jan was Deputy Laboratory Director of the Los Alamos National Laboratory, from 2006-2009. In this capacity, he was responsible for oversight and integration of the daily operations of the laboratory with focus on safety, security, business services, environmental management, and infrastructure. Jan has served as a board member of a number of companies, including Bechtel National, Inc., Kwajalein Range Services (Chair), Bechtel Bettis, Inc., Universities Space Research Association (Chair), and the Armed Services YMCA.

read more